Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2021-03-11 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2020年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2020 年度监事会工作报告" which translates to "2020 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's financial reports and internal controls during 2020. It includes references to the review and approval of quarterly and annual reports, internal control evaluations, and audit opinions. The document is a comprehensive report on the supervisory board's work and oversight for the year 2020, not just an announcement or a brief summary. It contains substantive content about the supervisory board's role and findings, which aligns with a Management Report type document. It is not an Annual Report (10-K) or Audit Report (AR) itself, but rather a supervisory board report on their oversight activities. Therefore, the best fitting category is Management Reports (MDA). The document length (2720 characters) is sufficient for a detailed report but not a full annual report, and it is not a simple announcement or certification. Confidence is high given the detailed supervisory content and the nature of the report.
2021-03-11 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the fiscal year ending December 31, 2020, issued by the board of directors of 普洛药业股份有限公司. It contains detailed descriptions of the company's internal control systems, evaluation criteria, scope, and conclusions about the effectiveness of internal controls over financial reporting and non-financial reporting. The document includes quantitative and qualitative standards for identifying internal control deficiencies and reports on the absence of major deficiencies. It also discusses governance, organizational structure, risk management, and other internal control related matters. This type of document is a standalone report focused on internal control evaluation and audit results, not a full annual report or financial statement. It is not an announcement or a brief summary but a comprehensive internal control audit report. Therefore, it fits the category of Audit Report / Information (AR). FY 2020
2021-03-11 Chinese
关于对公司使用自有闲置资金进行理财投资的独立意见
Governance Information Classification · 90% confidence The document is a statement of independent directors providing their opinion on the company's use of idle funds for financial investment. It references governance guidelines and internal control systems but does not contain financial statements or detailed financial data. The document is short (429 characters) and serves as an independent opinion rather than a full report or announcement of voting results. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or regulatory compliance filing either. The content aligns best with a Governance Information (CGR) type, as it relates to internal governance and oversight by independent directors.
2021-03-11 Chinese
关于对拟续聘会计师事务所发表的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the prior approval opinion on the proposal to reappoint an accounting firm for auditing the company's 2021 financial report and internal control. It references regulatory rules and the company's articles but does not contain actual financial data or a full audit report. The document is short (385 characters) and serves as an opinion or approval statement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or certification. Confidence is high due to clear context and content. FY 2021
2021-03-11 Chinese
关于拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the company's 2021 annual audit. It details the qualifications, independence, and integrity of the accounting firm and the approval process by the board and independent directors. There are no actual financial statements or audit results included, only information about the auditor appointment. The document length is 2885 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this is not the audit report itself but an announcement about the auditor appointment. According to the filing definitions, this fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other categories like Audit Report or Annual Report.
2021-03-11 Chinese
关于使用自有闲置资金进行理财投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company (普洛药业股份有限公司) regarding the use of its own idle funds for financial investment. It details the investment overview, specific investment amounts, risk analysis, risk control measures, and the independent directors' opinions. The document is relatively short (1542 characters) and does not contain financial statements or detailed financial data. It is an announcement about a financing-related activity (use of idle funds for investment) rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it concerns the company's capital usage and investment activities.
2021-03-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.